EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient AdherenceByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MDPublished: June 23rd 2026 | Updated: June 16th 2026
Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment DecisionsByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MDPublished: June 23rd 2026 | Updated: June 16th 2026
Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver SupportByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MDJune 22nd 2026
The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke ManagementByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MDJune 22nd 2026
Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine CarcinomaByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MDJune 22nd 2026